高级检索
当前位置: 首页 > 详情页

Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3 beta signaling pathway activation in glioma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Neuroscience Center, Shantou University Medical College, Shantou, China [2]Faculty of Medicine and Health, Lishui University, Lishui, China [3]Department of Pharmacology, College of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang, China [4]Sichuan Cancer Hospital & Institute,Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
出处:
ISSN:

关键词: cell proliferation cyclin D1 glioma Par6

摘要:
As the key factor of the polarity protein complex, Par6 not only regulates polarization processes, but also plays important roles in tumor metastasis and progression in many epithelium malignancy tumors. Here, we showed that Par6 is an essential component in glioma tumorigenesis. Our results indicated the aberrant expression of Par6 in malignant glioma tissues and cell lines. We found that the regulation of Par6 expression induces cell proliferation and tumor growth in vivo and in vitro. Additionally, RNA-seq revealed the effects of Par6 were associated with cyclin D1-regulated cell cycle progression in glioma cells. Moreover, our results demonstrated that the regulation of Par6 can enhance the activation of Akt/PI3K signaling pathway, and subsequently upregulate the expression level of GSK-3 beta protein, which then regulate cyclin D1-mediated cell cycle regulation. Furthermore, we found that TGF-beta-induced the upregulation of Par6 expression may be involved in this process. The pathological analysis confirmed the correlation between Par6 expression and the prognosis in human glioma tissues, suggesting the regulation of Par6 expression regulates glioma tumorigenesis and progression. Thus, our findings showed that Par6 might be a potential biomarker for the diagnosis and providing a therapeutic strategy for the treatment of malignant glioma.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 生物学 3 区 细胞生物学
最新[2023]版:
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 生物学 3 区 细胞生物学
JCR分区:
出版当年[2020]版:
Q1 BIOLOGY Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 CELL BIOLOGY
最新[2023]版:
Q1 BIOLOGY Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Neuroscience Center, Shantou University Medical College, Shantou, China
共同第一作者:
通讯作者:
通讯机构: [1]Neuroscience Center, Shantou University Medical College, Shantou, China [4]Sichuan Cancer Hospital & Institute,Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [*1]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 Renmin South Road, Chengdu, 610047, China. [*2]Neuroscience Center, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46407 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号